Last reviewed · How we verify

NCT06595407

Loss of Y Chromosome in Aortic Stenosis

Recruiting now Last updated 19 September 2024
What this trial tests

trial testing Blood analysis for loss-of-Y chromosome in Aortic Stenosis in 200 participants. Currently enrolling.

Timeline
15 August 2024
Primary endpoint
31 December 2025
1 June 2026

Quick facts

Lead sponsorUniversity of Virginia
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date15 August 2024
Primary completion31 December 2025
Estimated completion1 June 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Virginia

Who can join

40 and older, male only, with Aortic Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The most common heart valve disease in humans is aortic stenosis which is a critical narrowing of the valve through which the heart has to pump blood to the rest of the body. This condition occurs in 2-3% of adults over 65 years of age and when it progresses to a severe stage leads to heart failure and need for valve replacement procedures (including surgery and catheter-based replacement). Aortic stenosis has a strong male predominance. The purpose of this study is to evaluate whether loss of Y-chromosome from circulating blood cells in males, which has been associated with TGF-beta-related fibrosis of other organs, is associated with the development of aortic stenosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other University of Virginia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06595407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing